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Vivax series:
Can primaquine therapy for vivax
malaria be improved?
J. Kevin Baird1 and Karl H. Rieckmann2
1US Naval Medical Research Unit #2, American Embassy Jakarta, Fleet Post Office, Asia-Pacific 96520-8132, USA.
2Australian Army Malaria Institute, Weary Dunlop Drive, Gallipoli Barracks, Enoggera, QLD 4051 Australia.
The incidence and range of endemic malaria caused by
Plasmodium vivax has expanded during the past 30
years. This parasite forms hypnozoites in the liver,
creating a persistent reservoir of infection. Primaquine
(PQ), introduced 50 years ago, is the only drug available
to eliminate hypnozoites. However, lengthy treatment
courses and follow-up periods are not conducive to
assessing the effectiveness of this drug in preventing
relapses. Resistance to standard therapy could be wide-
spread. Studies are urgently needed to gauge this prob-
lem and to determine the safety, tolerability and
efficacy of shorter courses and higher doses of PQ.
Plasmodium vivax causes malaria in ,80 million people
annually, predominantly in Asia, the Western Pacific and
the Americas [1]. Although the incidence and geographic
range of endemic vivax malaria retreated substantially
between 1945 and 1970, expanding risk of vivax malaria
marks the period 1970 to today [2–6]. Almost half of North
America and large tracts of South America, Europe and
Asia stand receptive to endemic vivax malaria, including
latitudes as far north as Newfoundland in Canada,
Sweden in Europe, and Manchuria in Asia. In the southern
hemisphere, Argentina and Australia are also receptive
[7]. In temperate regions, seasonally abundant anopheline
vectors transmit infection, and the parasite lies latent in
the liver through seasons in which vector activity cannot
endure. In the tropics, P. vivax exploits the same
capability, but tends to relapse quickly because feeding
activity by competent vectors often occurs all year round.
Latent stages of P. vivax in the liver constitute an
important reservoir of infection. Attacking that reservoir
demands specific chemotherapy to kill the latent liver
stages. Primaquine (PQ) is the only drug available for this
purpose and its appropriate application constitutes a
crucial weapon against resurgent vivax malaria.
Relapse
The cycle of invasion, development within, and rupture of
red blood cells by merozoites, trophozoites and schizonts
causes clinical malaria. Hypnozoites lie dormant until
they develop to mature liver-stage schizonts containing
thousands of individual merozoites. The schizont bursts.
Merozoites spill into the bloodstream and infect red blood
cells. The ensuing course of clinical malaria is called a
relapse. Among the species of Plasmodium that infect
humans, only P. vivax and Plasmodium ovale form
hypnozoites and cause relapse. The likelihood of relapse
by P. vivax, and the duration between primary parasitemia
and relapse, varies, apparently in relation to latitude and
seasonal abundance of anopheline vectors. In general,
strains from temperate regions are less likely to relapse
(,30% risk) and tend toward longer latency (.6 months).
Tropical strains usually relapse (,80% risk), often on
multiple occasions (three or more), and begin doing so
within a couple of weeks after primary parasitemia [8,9].
Exceptions do routinely occur. For example, risk of relapse
by P. vivax in India seems inexplicably low for a subtropical
environment (between 5% and 15%).
Patients experiencing the debilitating fevers, chills,
nausea, vomiting and malaise associated with vivax
malaria obtain relief by taking chloroquine (CQ) or
quinine. These drugs attack the blood stages, but exert
no known direct effect against the liver stages of the
parasite. PQ is the only drug that can eradicate parasites
from the liver.
PQ as an antimalarial drug
PQ was first synthesized in the USA during the Pacific war
(1941–1945) as part of a massive undertaking of anti-
malarial drug development [10,11]. PQ is an analogue of
pamaquine, the first 8-aminoquinoline drug to be produced
during an earlier antimalarial drug development program
in Germany during the 1920s [12].
Unlike other widely used antimalarial drugs, PQ
exerts a broad spectrum of activity against various
stages of the parasite. It kills both latent and
developing asexual stages in the liver, and sterilizes
the sexual blood stages (gametocytes). A standard
regimen clears the blood of asexual trophozoites of
P. vivax [13–15], but fails to affect the same stages of
Plasmodium falciparum [16–18]. Neither its complex
metabolism nor mechanism of activity is fully under-
stood [19]. A wide variety of metabolites, some of them
highly reactive hydroxylated species, apparently dis-
rupt parasite mitochondrial membranes. This could
account for the relative susceptibility of parasite stages
with a paucity of mitochondria [20].
PQ offers a wide range of clinical applications. In many
endemic regions, a single 45 mg dose of PQ is administeredCorresponding author: J. Kevin Baird (bairdjk@namru2.med.navy.mil).
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with standard therapy for falciparum malaria as a
measure to block transmission [21]. PQ taken daily
effectively prevents infection by P. falciparum and
P. vivax [22–26]. Travelers can take presumptive therapy
following travel to prevent relapse. Anti-relapse therapy
following diagnosis of vivax malaria constitutes the
conventional use of PQ.
How effective is anti-relapse therapy?
Standard anti-relapse therapy is generally considered to
be a single daily adult dose of 15 mg PQ base for 14 days.
This well-tolerated regimen [27–29] emanated from early
experimental clinical studies showing that many strains of
P. vivax are nearly completely susceptible to a total dose of
210 mg PQ. In other trials performed at the same time, it
was realized that infections with the Chesson strain,
isolated from an American soldier infected in New Guinea
[30], required at least 22.5 mg daily (total dose of 315 mg
PQ) to prevent subsequent relapse [27,31,32]. Standard
therapy against Chesson P. vivax achieved only ,80%
efficacy. Because many infections acquired in Southeast
Asia and the Southwest Pacific area show similar toler-
ance of standard PQ therapy (,80% efficacy) [15,33–36], a
regimen of 30 mg daily for 14 days (420 mg total dose) is
widely recommended [21,35–37]. It is important to point
out that virtually all of the data showing that standard
PQ therapy works well (.90% efficacy) is at least 40 years
old. The same is true even of the 30 mg daily regimen
with the exception of two relatively recent studies from
Thailand [15,34].
An alternative regimen for PQ-tolerant infections is the
intermittent, weekly administration of 45 mg PQ for 8
weeks (360 mg total dose of PQ). This is based on early
observations by Alving et al. [31] that this regimen
mitigated the hemolytic effects of PQ in individuals with
the less severe A2 variant (the most common mutant
genotype in sub-Saharan Africa) of glucose-6-phosphate
dehydrogenase (G6PD) deficiency. The 8-week regimen
also appeared to be more effective than a daily dose of
15 mg against infections with the Chesson strain [31]. We
are not aware of recent data demonstrating the efficacy of
this regimen.
These long courses of treatment and follow-up do not
encourage assessment of the efficacy of PQ. Consequently,
little information is available about the efficacy of such
regimens against naturally acquired infections, or about
the prevalence or extent of hypnozoites that tolerate or
resist standard PQ therapy.
Can PQ treatment be improved?
Shorter regimens improve compliance. The major dis-
advantage of prolonged daily or weekly courses of drug
administration is patient compliance. In a series of studies
with American soldiers repatriated from Vietnam, the
odds for relapse in groups that were not supervised during
standard PQ therapy was 4.4 times greater than in
the supervised groups [38–40] (Fig. 1). Compliance with
a 14-day regimen is a problem.
In many endemic countries, 15 mg PQ per day for 5 days
(75 mg total dose) has long been used to prevent relapse.
However, recent well-controlled clinical trials in Pakistan
[41] and India [42] showed this short, low-dose regimen to
be ineffective. Both studies demonstrated almost no effect
on the risk of relapse. Nonetheless, we believe that
similarly abbreviated treatment courses that deliver an
adequate total dose could prove highly effective.
Pre-clinical studies in nonhuman primates showed that
the total dose of PQ, rather than schedule of dosing,
determined the efficacy of treatment [43]. Clinical studies
corroborated that view [31,44]. A total dose of 360–420 mg
PQ delivered over a period of 7 days, 14 days or 8 weeks
prevented relapse of the PQ-tolerant Chesson strain of
P. vivax equally effectively. All strains of P. vivax except the
Chesson strain proved susceptible to a total dose of 210 mg
PQ in experimental challenge studies conducted 50 or
more years ago. Recent demonstrations of susceptibility to
standard PQ therapy, without potentially serious con-
founding factors such as re-infection or recrudescence, are
not available. Two studies from Thailand represent
important exceptions demonstrating poor performance of
the 210 mg total dose delivered over 14 days [15,34]. A
higher dose than 210 mg of PQ might be necessary in areas
of established tolerance or resistance (e.g. Southeast Asia
and the Southwest Pacific).
Higher doses could improve efficacy. In areas where a
total dose of 210 mg is still effective, this dose could be
administered over as few as three days (30 mg, twice a day
for three days, and once on the fourth day). However, in the
Asia and Pacific regions, for an apparently increasing
number of vivax infections, the 210 mg or even the
315 mg dose no longer cures ([15,21,33–36]; J.K. Baird
and K.H. Rieckmann, unpublished). Treatment with a
total dose of 420 mg (or 6 mg kg21 for a person weighing
70 kg) would almost certainly achieve higher cure rates
than the 210 mg standard. This total dose, given as 60 mg
daily for 7 days to 11 subjects [44], was just as effective as
Fig. 1. Relapse of Plasmodium vivax in American soldiers repatriated from Viet-
nam. These American soldiers were given supervised or unsupervised standard
primaquine (PQ) therapy of 15 mg daily for 14 days. Patients were followed for 4–
12 months after therapy. The number of patients who experienced a relapse (pur-
ple bars) or no relapse (red bars) are indicated. The odds ratio for relapse among
unsupervised soldiers was 4.4 (95% confidence interval ¼ 2.2 to 8.3; P , 0.0001).
Adapted from data in Refs [38–40].
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30 mg daily for 14 days, or 45 mg weekly for 8 weeks, and
was more effective than 15 mg daily for 14 days against the
Chesson strain. Provided tolerance is good, higher daily
doses for a shorter period of time would almost certainly
improve patient compliance.
Tolerability and safety of high dose PQ
Clayman et al. [45] gave a range of single doses of PQ to
fasted volunteers. They reported abdominal distress in 5%,
10%, 35% and 100% of subjects given 15 mg, 30 mg, 45 mg
or 90 mg of PQ, respectively. Doses of 120 mg (in 18
subjects) or 240 mg (in 5 subjects) caused immediate and
severe abdominal cramping. However, the same report
describes complete relief from these effects, even at the
highest doses applied, when PQ was administered with
food. Administration of 30 mg PQ daily with a snack for 16
to 52 weeks was as well tolerated as the placebo in
prophylactic trials [22–24,26].
Although gastrointestinal complaints were not a very
prominent feature in volunteers receiving daily doses of
60 mg [15,44], further studies in various ethnic groups are
needed to determine the tolerability and safety of such
doses administered over a period of 3–7 days. The same
would of course apply to higher daily doses given over a
shorter period of time. Such studies should include
monitoring for any potential cardiac, hepatic, renal and
hematological toxicity.
PQ causes mild methemoglobinemia in normal subjects
given standard therapy. Peak levels of ,5% methemo-
globinemia are typical during PQ therapy, and sometimes
reach up to 15% in normal subjects. Methemoglobinemia of
,20% does not cause symptoms or signs in most people.
Methemoglobinemia in subjects given 30 mg daily for 20
weeks or 52 weeks was no more pronounced than in
subjects receiving standard therapy of 15 mg daily for
14 days [22,26]. PQ-induced methemoglobinemia thus
appears mild and self-limited for most people. The impact
of higher doses over shorter periods on methemoglobine-
mia has not been evaluated, although Clayman et al. [45]
did not report signs or symptoms of methemoglobinemia in
the subjects they exposed to very high doses of PQ (up to
240 mg). Some people suffer an inborn deficiency of
methemoglobin reductase and are sensitive to PQ-induced
methemoglobinemia (2–30% with long-term weekly 45 mg
of PQ, see Ref. [37]).
What about G6PD deficiency?
PQ causes acute intravascular hemolysis in people having
a genetic deficiency of glucose-6-phosphate dehydrogenase
(G6PD). Many dozens of variants of this abnormality occur
in varying degrees of frequency among most human
populations [46]. It is especially common among people
originating from highly malaria-endemic regions, for
example, sub-Saharan Africa, where 5–10% of people
typically express the trait. Each variant carries between
0% and 100% normal enzyme activity. The level of residual
G6PD activity does not always correlate with the severity
of drug-induced hemolysis. PQ could cause a mild, self-
limited hemolysis of senescent erythrocytes, as in the
African A2 variant, or a relatively severe and dangerous
hemolysis, as in the Mediterranean B2 variant. In the
absence of definitive evidence of either G6PD-normal
status or demonstrated tolerability in a given variant, PQ
should not be administered. This restricts the use of PQ in
the setting of interventions against epidemic or endemic
vivax malaria. An inexpensive and reliable point-of-care
diagnostic kit would solve this problem. The available
NADPþ spot test (Sigma Chemical Co., St. Louis, MO,
USA), among others, provides a reliable and relatively
inexpensive (,US$1) diagnostic test, but requires a labora-
tory setting and skilled hands. Further efforts are needed to
develop affordable and simple field kits for identifying
individuals that are susceptible to PQ hemolysis.
How should alternative PQ regimens be evaluated?
The effectiveness of PQ treatment regimens should be
assessed in different ethnic groups. Such studies must also
monitor and document the safety and tolerability of the
treatment regimens, especially for gastric discomfort and
methemoglobinemia. Initially, experimental regimens
should be administered only to G6PD-normal, non-
pregnant individuals.
Health care providers or responsible members of the
patient’s family should directly observe therapy. Ideally,
compliance would be signature-affirmed by both the patient
and the monitor. Unsupervised therapy, especially over a
long period, comes with high risk of poor compliance.
Assessment of the efficacy of PQ treatment should be
done in patients who have returned to non-endemic areas
and are willing to undergo directly observed therapy
followed by lengthy periods of follow-up (at least 2 months,
preferably 18 months). The efficacy of PQ therapy usually
cannot be assessed confidently in patients residing in
endemic areas because re-infection cannot be ruled out.
However, patients returning to large cities in endemic
areas are very unlikely to be re-exposed to malaria (except
in and around the Indian sub-continent where Anopheles
stephensi transmits malaria within cities). Likewise, re-
infection might be excluded in patients residing at high
altitudes where anopheline mosquitoes do not occur,
despite abundance at lower altitudes.
Companion blood schizonticides in PQ therapy
A diagnosis of vivax malaria usually prompts therapy with
both chloroquine (CQ) and PQ because CQ has tradition-
ally been the drug of choice for aborting an acute attack of
vivax malaria. However, in 1989, resistance to CQ was first
documented in P. vivax from Papua New Guinea [47].
Since then, CQ resistance has been shown to occur in Asia
[21,48–51] and the Americas [52,53]. In eastern Indonesia,
the risk of therapeutic failure approaches 80% within
28 days [51].
Unrecognized resistance to CQ could create the false
impression of ineffective PQ therapy. Conversely, ordi-
narily effective CQ levels (.100 ng ml21) persist in the
blood for about a month and will suppress relapse due to
ineffective PQ therapy. This might lead to the false
impression of effective PQ therapy. The therapeutic
response to CQ represents a potentially powerful con-
founding factor in assessing PQ efficacy (Fig. 2).
Because quinine is rapidly excreted (almost completely
within 24 h), the drug does not have the effect of
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suppressing subsequent relapse. The available data point
to Day 16 post-patency of the primary parasitemia as the
earliest relapse and, for tropical P. vivax from the western
Pacific region, most have relapsed at least once by Day 45.
By contrast, onset of recurrent parasitemia after CQ
treatment of CQ-sensitive P. vivax (CSPV) infections is
suppressed because the blood CQ plus desethylchloro-
quine (CQ þ DCQ) levels remain above the minimal
effective concentration (MEC) (,100 ng ml21). CQ-resistant
P. vivax (CRPV) infections rapidly develop recurrent (in
some cases persistent) parasitemia in the face of ordinarily
effective CQ þ DCQ levels. Recurrence of parasitemia
within one month after treatment is due to either
a recrudescence (persisting blood stages) or a relapse
(persisting liver stages) of a CRPV infection.
In areas where resistance to CQ occurs, it is difficult to
distinguish recrudescence from relapse after CQ and/or
PQ treatment. Therefore, we recommend supervised
treatment with quinine and PQ to minimize uncertainties
surrounding the curative efficacy of PQ. There is much
data to support the supposition that quinine therapy
completely eliminates the blood stages of P. vivax [54]: no
recrudescence occurred among volunteers challenged with
blood stages and treated with quinine. Quinine is excreted
far more rapidly than CQ, and MECs of quinine persist for
less than one day after treatment. Therefore, a recurrence
of parasitemia following adequate compliance with qui-
nine plus PQ therapy would almost certainly represent a
relapse and thus failed PQ therapy.
Interactions between blood schizonticides and PQ in
eliminating liver stages could confound the interpretation of
outcomes of PQ therapy. A series of experimental challenge
studies [27,32] demonstrated apparent synergy between
blood schizonticides, such as CQ or quinine with PQ, in
preventing relapse. Whereas CQ and quinine alone exert
no discernible effect upon the ability of hypnozoites to
cause relapse [54], these drugs profoundly improved the
performance of PQ in doing so [27,32]. When PQ was not
administered concurrently with CQ or quinine, it performed
very poorly. We are not aware of any hypothesis explaining
this phenomenon. The apparently impaired efficacy of PQ as
monotherapyagainst hypnozoites isneither widely citednor
recognized. Administering PQ concurrently with CQ or
quinine might help ensure that anti-relapse therapy is not
impaired, as illustrated in Fig. 3.
Novel PQ treatment regimens
The resurgence of vivax malaria in many parts of the world
emphasizes the importance of having a more effective cure
for the disease. An inadequate attack on the hypnozoite
reservoir of infection would almost certainly contribute to
further deterioration of the malaria situation. Gauging the
adequacy of widely applied regimens of PQ therapy thus
constitutes an imperative in formulating rational inter-
ventions against endemic vivax malaria. The available
data shed little light on this question in almost any area
of the world. Relapse after PQ therapy is widely reported
[35,36,55–59], but it is difficult to ascertain the primary
determinant of therapeutic failure (i.e. poor patient
compliance with the lengthy treatment regimens or the
presence of PQ-tolerant or PQ-resistant parasites).
The operational necessity for evaluating PQ therapy in
malaria control practice should be exploited to also
evaluate novel new regimens of PQ that deliver higher
doses over shorter periods. In the past, higher doses and
shorter courses of treatment have not been evaluated
because of the perception that PQ is often not well
tolerated by the gastrointestinal tract. This perception
could be due to the fact that little attention has been paid to
the importance of taking the drug with food. The severe
hemolytic reactions observed in some individuals with a
G6PD deficiency also tempers efforts to evaluate alternative
regimens using higher doses of PQ. That danger is real.
Although most G6PD-deficient individuals experience
only a mild and self-limiting hemolysis after taking PQ
(even with as much as 30 mg daily taken over many weeks
Fig. 2. Relapse of tropical Pacific Plasmodium vivax after standard therapy with
quinine and chloroquine. (a) Quinine is a rapidly eliminated drug that does not
suppress relapses. Relapses commenced ,16 days after patency of the original
infection, and most patients relapsed within 45 days from the onset of patent para-
sitemia (post-patency). (b) Chloroquine (CQ) therapy has a different impact on the
timing of relapses or recrudescences in tropical Pacific vivax malaria. CQ-sensitive
P. vivax (CSPV) (purple line) remains suppressed for ,30 days by persisting con-
centrations of CQ plus desethylchloroquine (CQ þ DCQ; green line) that are higher
than the minimum effective concentration (MEC; broken black line). Relapse (or
recrudescence) caused by CQ-resistant P. vivax (CRPV; red line) occurs much ear-
lier because parasites are no longer suppressed by drug concentrations higher
than the MEC (for sensitive parasites). Data adapted from Ref. [60].
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[31]), among the rare G6PD variants, the reaction to PQ
(and other drugs) can be life threatening. Development of a
point-of-care G6PD deficiency diagnostic test, especially
one that identifies those at risk of severe hemolysis, would
constitute a tremendous advance that will markedly
improve the use of PQ as a tool against the broadening
encroachment of vivax malaria.
Ideally, PQ would be replaced by a drug that is well
tolerated, safe without special diagnostics, and easily
administered over a brief period. The US Army and
GlaxoSmithKline have a PQ analog named Tafenoquinee
in Phase III clinical trials. This drug shows promise in
addressing some of the pitfalls of PQ therapy, but it is not
yet available. In the meantime, PQ already rests on the
shelves of most pharmacies and clinics in endemic areas of
the world, and every effort should be made to use it
effectively. When aiming for higher doses over shorter
periods of time, toxicity and safety become paramount
concerns that should be evaluated carefully in at least
several ethnic groups.
Conclusions
PQ is widely available and affordable in the endemic
developing world. It is the only available drug that can
eliminate hypnozoites, an important latent reservoir of
infection. However, the effectiveness of PQ in preventing
relapses has not been assessed adequately because of
practical difficulties associated with lengthy treatment
courses and follow-up periods. Shorter regimens or higher
doses, or both, could markedly improve the ease of
administration and efficacy of PQ. We recommend using
quinine therapy when assessing the efficacy of PQ, with
either standard or novel PQ regimens. Realizing the full
potential of PQ in an endemic setting, however, would
require a point-of-care diagnosis of G6PD deficiency.
Evaluation of such drug regimens and supporting devices
are urgently needed in a variety of ethnic groups to
effectively attack an expanding reservoir of infection and
encroaching endemic risk.
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